CJC-1295 — compound monograph
Growth-hormone-releasing hormone analogue with albumin-binding drug affinity complex. Unapproved, research supply. The Institute assesses 3 outcomes for this compound and grades the strongest at low certainty.
§1Identification and status
§1.1Nomenclature
- Preferred name
- CJC-1295
- Compound class
- Growth-hormone-releasing hormone analogue with albumin-binding drug affinity complex
- Assessment series
- Growth-hormone axis
- Synonyms and codes
- CJC-1295 with DAC · DAC:GRF · modified GRF(1-29) (the non-DAC variant) · CJC-1295 DAC
- Route as evaluated
- Subcutaneous
§1.2Chemistry
Chemical identifiers are reproduced where they are public. Where a structure has not been published the monograph records not disclosed rather than constructing one.[1]
- CAS registry number
- 863288-34-0 (DAC variant); 863288-34-0 is frequently misapplied to the non-DAC variant
- Molecular formula
- C165H269N47O46 (DAC variant)
- Average mass
- 3647.2 (DAC variant); 3367.9 (non-DAC modified GRF(1-29))
- Monoisotopic mass
- not reliably published
- ATC classification
- not assigned
§1.3Sequence and structural notes
Two distinct compounds are sold under this name and confusing them is the dominant analytical problem. **Modified GRF(1-29)**, often mislabelled "CJC-1295 no-DAC", is a 29-residue tetrasubstituted GRF analogue of about 3368 Da with a half-life of roughly 30 minutes. **CJC-1295 with DAC** adds a C-terminal lysine bearing a maleimidopropionyl group that forms a covalent thioether bond with cysteine-34 of circulating albumin, giving a half-life measured in days. The two have entirely different pharmacology and differ by approximately 280 Da. The Institute regards a certificate that does not state which variant was synthesised as having failed identity.
§1.4Assessment status
The Institute assesses CJC-1295 across 3 indications and grades the strongest of them at low certainty. Supplied as a research chemical; no marketing authorisation for the uses under which it is supplied.
Table 1. Assessed outcomes for CJC-1295, ordered by certainty. Each row links to the per-indication evidence extract.
| Indication | Effect as recorded | Certainty | Trials |
|---|---|---|---|
| Growth hormone deficiency and growth-hormone secretagogue pharmacology | Mean IGF-1 increased 1.5- to 3.0-fold above baseline and remained elevated for 6 to 11 days after a single dose in a phase 1 study of 11 participants | Low | 2 |
| Biological ageing and healthspan endpoints | No randomised human evidence identified | Very low | 0 |
| Sarcopenia and lean-mass preservation during weight reduction | No randomised human evidence identified | Very low | 0 |
| Effects are reproduced as the contributing trials reported them. Where a confidence interval is held it appears on the per-indication extract rather than in this summary table. | |||
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH Harmonised Tripartite Guideline 1999;Step 4 version. identifier not held by the Institute
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.